51ÁÔÆæ

Please note that functional cookies must be enabled to listen to a podcast.

With the Covid-19 pandemic now in check, we look back on how pharmaceutical manufacturers worldwide faced Emergency Use Authorization (EUA) problems to keep their supply chains intact.

In this episode of 51ÁÔÆæ Radio, host Erika Porcelli and guests Susan Schniepp, 51ÁÔÆæ Distinguished Fellow and Parental Drug Association (PDA) Chair-Elect, and Lisa Michels, 51ÁÔÆæ’s General Counsel & Regulatory Affairs Expert, discussed the regulatory impacts of Emergency Use Authorization as well as how to address and try to overcome the distancing regulations that had to be put in place.

Listen in as we go over Emergency Use Authorization expedited approvals, relevant regulatory impacts, and the FDA’s long-term inspection strategy moving forward.

To begin the 51ÁÔÆæ scoping process today, please enter your information in the blue form below and click the submit button at the bottom of the webpage.